A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)
The combination of Palbociclib plus letrozole has a favorable toxicity profile and appears to have clinical activity in recurrent hormone receptor-positive high-grade ovarian cancer.
Authors
- Graziela Zibetti Dal Molin (ORCID: https://orcid.org/0000-0002-8987-0066)
- Rafaela Gomes de Jesus (ORCID: https://orcid.org/0000-0001-6912-2995)
- Elias Abdo Filho
- Aknar Calabrich (ORCID: https://orcid.org/0000-0002-0641-5683)
- Andréia Cristina de Melo (ORCID: https://orcid.org/0000-0002-1201-4333)
- Mirela Foresti Jiménez (ORCID: https://orcid.org/0000-0002-9579-5592)
- Gustavo Werutsky (ORCID: https://orcid.org/0000-0001-6271-105X)
- Taiane Francieli Rebelatto (ORCID: https://orcid.org/0000-0001-7306-5428)
- Fernanda Damian (ORCID: https://orcid.org/0000-0003-4651-3357)
- Angélica Nogueira‐Rodrigues (ORCID: https://orcid.org/0000-0002-3405-8310)
Institutions
- Universidade Federal de Minas Gerais (BR)
- Universidade Federal do Rio Grande do Sul (BR)
- Universidade Federal de Ciências da Saúde de Porto Alegre (BR)
- Eastern Cooperative Oncology Group (US)
- Instituto do Câncer do Estado de São Paulo (BR)
- Hospital de Clínicas de Porto Alegre (BR)
- Beneficência Portuguesa de São Paulo (BR)
- Hospital Nossa Senhora da Conceição (BR)
- Grupo Hospitalar Conceição (BR)
- Instituto Nacional de Câncer - INCA (BR)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.ygyno.2025.05.022
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Instituto Científico Pfizer